NCT03850366View on ClinicalTrials.gov

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Hematological Malignancy

Interventions

DRUG

Bortezomib

GVHD prophylaxis

Trial Locations (1)

48202

RECRUITING

Henry Ford hospital, Detroit

All Listed Sponsors

lead

Henry Ford Health System

OTHER

NCT03850366 - HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib | Biotech Hunter | Biotech Hunter